Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 10Carcinoma, Hepatocellular 5Colonic Neoplasms 4Rectal Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Adenocarcinoma 2Thrombocytosis 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Physician Education 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Noonan Syndrome 6 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Pancreatic Adenocarcinoma 1Melanoma 1MSI-H Colorectal Cancer 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1

Interventions

regorafenib 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Pancreatic Adenocarcinoma × regorafenib × Clear all
NCT02383433 2023-10-23

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 8 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡